Dear Coalition,

We hope you are all having a beautiful summer! We'd like to share several important updates and events in the psychedelic medicine community. Tomorrow, don't miss the Psychedelics Today webinar featuring our executive director, Kate Cotter, where she'll share about the importance of state and local policy reform, the various alternatives to prohibition, and our efforts here in Nevada.

We'll also recap the recent FDA decision to deny the Lykos' New Drug Application (NDA) for MDMA-assisted therapy for PTSD. Additionally, check out Sam Harris's thought-provoking podcast, "The Future of Psychedelic Medicine 2."

Last but not least, if you are interested in 12-month comprehensive psychedelic training for practitioners and professionals, consider enrolling in Psychedelics Today's Vital training program--enrollments are now open!

Scroll down to learn more, and as always, thank you for your advocacy and dedication to our shared mission to bring healing.

- The NCPM Team

Psychedelic Policy in Nevada - Webinar Tomorrow!

Thank you to Psychedelics Today for inviting us to join their livestream and free Vital Training webinar tomorrow, Thursday, 10 AM PST, to discuss our policy reform efforts here in Nevada!

“What can Nevada lawmakers learn from Oregon and Colorado’s pioneering efforts in psychedelic policy reform as they consider new bills for the 2025 session? 

We’re excited to host Kate Cotter, executive director of the Nevada Coalition for Psychedelic Medicines, for a webinar on Nevada’s Senate Bill 242, which established a Psychedelic Medicines Working Group. Despite initial skepticism, the bill gained bipartisan support and passed with a landslide victory. 

This webinar will cover implementing state and local initiatives, decriminalization vs. legalization, current psychedelic policy reform in the US, and Nevada’s future prospects and implications for other states.”

Register now to join the conversation.

FDA Denies Lykos' Application for MDMA-AT

On August 9th, the FDA denied Lykos Therapeutics' New Drug Application (NDA) for MDMA-assisted therapy for PTSD, citing insufficient data and requesting an additional Phase 3 study. The decision was anticipated following concerns about safety risks and study design raised by the FDA's advisory committee. Lykos, veterans' advocacy groups, and many others expressed disappointment, emphasizing the impact on veterans suffering from PTSD. Lykos plans to request a meeting with the FDA to discuss resubmission options.

For more details, read Ann Harrison's article in Lucid News here.

The Future of Psychedelic Medicine 2

Sam Harris speaks with Dr. Jennifer Mitchell and Dr. Sarah Abedi about recent developments in research on psychedelics. They discuss the history of this research and the war on drugs, recent setbacks in the FDA approval process, MDMA as a treatment for post-traumatic stress disorder (PTSD), the challenges of conducting this research, allegations of therapist misconduct, new therapeutic models for mental health treatment, psychoneuroimmunology, "non-psychedelic" psychedelics, good and bad trips, the FDA's coming decision on MDMA-assisted therapy, "right-to-try" policies for pharmaceuticals, the role of psychedelic therapists, the problem of having all this therapeutic work being done underground, and other topics.



Listen to the epidode here.

Psychedelics Today's Vital Training

Open for Enrollment

We are often asked about psychedelic training programs, so we wanted to let you know that Psychedelics Today's Vital training is now open for enrollment! Vital is a comprehensive 12-month education course — ideal for medical specialists, mental health professionals, therapists, and wellness practitioners seeking to integrate psychedelic knowledge into their practice. Scroll down for more information and/or learn more here.